GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

FOUR months into 2025, the usually violence-plagued community of Grants Pen in St Andrew has recorded only one murder up to Sunday, and stakeholders, including the police, have high hopes that the ...

AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...

Elections Canada wants you to know your ballot will count whether you mark it with a pen or with a pencil. The independent agency says it’s seeing posts on social media claiming voters have to ...

Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.

Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...

For example, spending for Ozempic increased from $0.4 billion to $26.4 billion, but combined spending on Victoza, Bydureon and Byetta decreased by $4 billion from $7.1 billion to $3.1 billion.

Restricting your carbohydrate intake can “reap the metabolic effects associated with short-term fasting”, a new study has revealed. Researchers from the University of Surrey have found that limiting ...

For example, spending for Ozempic increased from $0.4 billion to $26.4 billion, but combined spending on Victoza, Bydureon and Byetta decreased by $4 billion from $7.1 billion to $3.1 billion.

Shift workers are less likely to develop cardiovascular complications if they only eat in the daytime, latest research has suggested. Researchers from Mass General Brigham have found that eating ...

New data documented dramatic shifts in prescribing for both type 2 diabetes (T2D) and weight loss, particularly with the uptake of tirzepatide (Lilly) and declines in the use of older agents.